MedPath

Artificial Shrinkage for Human Blastocyst Prior Vitrification

Not Applicable
Conditions
Vitrification
Interventions
Procedure: Artificial shrinkage
Registration Number
NCT02976662
Lead Sponsor
Dar AlMaraa Center
Brief Summary

Investigators aim to investigate the effect of elimination of blastocoelic fluid by creating a large hole in the zona pellucida at the cellular junction of the trophectoderm cells located far away from the inner cell mass with a laser pulse before vitrification.

Detailed Description

Human blastocyst formation begins about 5 days after injecting a single sperm into an oocyte in ICSI cycle or incubation of them in IVF cycle. Human blastocyst consists of cells forming an outer layer called trophotoderm that will form the placenta in case of successful implantation, an inner cell mass which become the fetus, a fluid-filled blastocoel cavity in the center, and a surrounding zone pellucida from which the embryo hatches to implant in the uterus. Human blastocyst contains a large amount of liquid in the blastocoel, which alters the infiltration of vitrification solution during the vitrification procedures leading to ice crystal formation. Therefore, investigators need to compare blastocyst survival, clinical pregnancy and implantation rates between vitrified untreated expanded blastocysts and vitrified blastocysts with artificially eliminated blastocoels by a laser pulse prior to vitrification

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
100
Inclusion Criteria
  • BMI of ≤ 32
Exclusion Criteria
  • Non-expanded blastocysts.
  • Women who had uterine pathology or abnormality.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Artificial shrinkageArtificial shrinkageElimination of blastocoelic fluid by creating a large hole in the zona pellucida at the cellular junction of the trophectoderm cells located far away from the inner cell mass with a laser pulse before vitrification.
Primary Outcome Measures
NameTimeMethod
Implantation rate1 month

number of intrauterine gestational sacs over the total number of embryos transferred

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Yasmin Magdi

🇪🇬

Benha, Egypt

© Copyright 2025. All Rights Reserved by MedPath